Egypt Pharmaceuticals and Healthcare Report Q2 2013

Business Monitor International Market Research Reports Market Reports Online XML Feed

Egypt Pharmaceuticals and Healthcare Report Q2 2013 Mar 13th 2013, 00:00 BMI View: Geographic diversification and investment into the pharmaceutical and healthcare sector ofemerging economies such as Egypt may be a favourable strategy for any multinational drugmaker.However, despite our forecast for steady growth in the Egyptian pharmaceutical market, it is vital thatcompanies recognise the risks. Downside risks to our forecast, in addition to the country''s state ofpolitical and economic flux, are: the patent cliff, pricing, higher domestic drug production output anda diversification of drugs available at competitive prices in the generic drug sector.Headline Expenditure Projections?? Pharmaceuticals: EGP14.99bn (US$2.48bn) in 2012 t...

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions